Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Wilhelm

Showing results (41-50 of 42) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 42 results.
Cancer Research|October 7, 2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisScott M Wilhelm, Christopher Carter, Liya Tang, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2002
Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitorJacques Dumas, Holia Hatoum-Mokdad, Robert N Sibley, et al.
Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 42 results.
Cancer Research|October 7, 2004
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisScott M Wilhelm, Christopher Carter, Liya Tang, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2002
Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitorJacques Dumas, Holia Hatoum-Mokdad, Robert N Sibley, et al.
Pageof 5